NEW

Italians Share Novel Operating Room Research Using UVDI-360 Room Sanitizer

UltraViolet Devices Inc. (UVDI) has announced new research demonstrating the UVDI-360 Room Sanitizer’s rapid disinfection of operating rooms between surgical procedures will be presented at this month’s Society for Healthcare Epidemiology of America (SHEA) Spring Conference.

The Joint Commission issues Sentinel Event Alert on optimizing medication safety with smart infusion pumps

A new Sentinel Event Alert from The Joint Commission, “Optimizing smart infusion pump safety with DERS,” describes how built-in dose error reduction software (DERS) can improve patient safety.

Hensler Bone Press Receives CE Certification

Hensler Surgical Technologies has announced its newly obtained CE mark for the Hensler Bone Press (HBP).

Healthmark Offers New Anti-Fatigue Mat

Healthmark Industries has introduced an Anti-Fatigue Mat to its Personal Protection Equipment (PPE) product line.

O2 RegenTech Receives $600,000 to Develop Oxygenating Wound Treatments

O2 RegenTech, a medical technology company focused on wound care solutions, has been awarded a $225,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing. Additionally, the company received a $225,000 National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150,000 from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).

The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, there are no wound treatments available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech aims to make wound care simpler with its proprietary product, OXAID™, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing.

“O2 RegenTech is extremely excited to receive the support of the NSF, the NIH, and the OTF,” said Dr. Andreas Inmann, President & CEO of O2 RegenTech. “This funding validates our approach and will be instrumental in moving our technology closer to regulatory submission and commercialization.”

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X